gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin vertex expand gene edit capabl
highlight week june june unrat announc enter
definit agreement acquir exon therapeut privat million up-front potenti addit mileston
payment well expans exist collabor agreement crispr buy
acquisit collabor provid vertex gene edit capabl duchenn muscular dystrophi dmd
myoton dystrophi type view news posit signal crispr foray vivo gene
edit continu big cap interest genet medicin includ gene edit axov gene therapi
buy announc follow-up data sunrise-pd phase ii trial lentiviral-bas gene
therapi gt axo-lenti-pd parkinson diseas pd axov also announc discontinu collabor
benitec biopharma unrat affirm expect dataset gangliosidosi
asset bluebird bio unrat announc eu condit market author lentiviral-bas ex vivo gt
zynteglo patient year older transfusion-depend beta-thalassemia tdt
look forward june june june et nation institut nih
lysogen unrat particip workshop live broadcast central nervou system immunogen
consider aav-bas june european hematolog associ eha host annual
congress amsterdam program includ repres bluebird bio unrat celyad unrat edita
medicin buy kite gilead unrat compani sr-tiget privat
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
studi publish june journal scienc buy co-found feng zhang group
broad institut report new approach target direct insert transgen use rna-guid crispr-
associ transposas cast system achiev insert effici uniqu site coli
genom gene edit insert highli local occur dna base pair pam
site howev unlik crispr edit insert occur independ homolog recombin hr machineri
due distinct mechan dna modif next step clear optim system use eukaryot
cell determin whether report off-target insert rate target effici may reduc
import recal nuclease-bas gene edit approach shown great efficaci gene disrupt
target disrupt effici well report variou system howev target transgen insert
effici lag behind due lower effici hr-base dna repair process use insert gene vs non-
homolog end join nhej mediat gene disrupt ineffici hr cell activ
divid thu limit cell popul could potenti target
approach achiev homology-independ target integr hiti develop academ
group well intellia buy privat number present
topic appear american societi gene cell therapi asgct annual meet howev
also reli standard crispr nucleas mean larg fraction dna break repair nhej
note unlik hr-base insert transgen insert cast scarless mean element transposon
system incorpor either end intend transgen would preclud approach
pleas refer import disclosur inform regul analyst certif found page report
use insert sequenc middl exon therapeut purpos correct point mutat howev
author suggest would suitabl insert sequenc intron non-cod sequenc well
safe harbor loci driven endogen promot done albumin gene
vblt neutral pt data aim defin respons characterist june livshit
vbl announc poster present american societi clinic oncolog annual
meet chicago final data phase i/ii trial therapi platinum-resist ovarian
cancer radiograph analysi patient phase ii studi recurr glioblastoma gbm
ovarian cancer present show evalu patient treat therapeut dose
show reduct biomark howev reduct show trend
toward longer surviv day vs day reach statist signific valu
gbm present present investig ucla brain tumor imag laboratori btil highlight
radiograph signatur seen respond data provid rational support investigator-initi
random control phase ii studi gbm slate begin readout anticip
us interest data appreci modifi gener cautiou view prospect
program await interim analys ovarian visibl follow-up studi gbm
buy pt ahead profit zolgensma sma june amusa
believ analyst unwil unabl model compani portfolio intern
extern license program updat detail model account far program
consensu model includ zolgensma launch broad label increas pt
also pose follow question believ expos irrat low consensu estim
 model profit zolgensma
 extern license product mani explicitli model mani account total
 total/averag sale partner product
 weighted-averag royalti appli license product
 royalti unrat potenti infring parti model
 higher profit licens revenu reflect model
drop coverag nightstar unrat nightstar june announc
complet acquisit nightstar
crsp buy doubl crispr expand collab exon buy june livshit
vertex pharmaceut unrat announc build-out gene edit footprint via acquisit exon
privat expans exist crispr collabor goal develop
therapi dmd
vertex acquir outstand share exon mm up-front possibl addit payment
exon sharehold bn base develop regulatori mileston expand
agreement crispr receiv up-front payment mm potenti regulatori
commerci mileston payment bn includ up-front well tier royalti payment net
sale vertex also announc appoint dr john gray former cso buy-rat neuromuscular aav-bas
gt compani audent therapeut svp genet therapi
see partnership good move crispr first major foray vivo gene edit addit
vertex acquisit exon signal continu big-cap interest genet medicin build momentum
neuromuscular gene edit brisk activ gt space half wonder gene
edit follow suit
buy valuat make good entri data june amusa
axov gene therapi announc interim data cohort sunrise-pd phase ii trial
lentiviral-bas gt axo-lenti-pd parkinson diseas pd discontinu
collabor benitec biopharma unrat expect dataset
axo-lenti-pd data larg consist prior data littl mitig chief
concern though axov discuss potenti axo-lenti-pd set new label standard reiter
caution earli pd data name potenti exist placebo hawthorn effect
page
believ discontinu licens collabor benitec neg show abil axov
fail fast without unnecessarili spend resourc posit
us interest catalyst gangliosidosi readout expect
gangliosidos see higher potenti asset transform axov valuat given fatal
natur diseas life expect year therapi approv disease-modifi treatment
low amount enzym product might abl transform clinic outcom
genet medicin news june june
unrat present data on-going studi control platform june
trvx ol unrat announc public data studi combo june
unrat announc promot emili hill chief offic june
unrat announc eu condit market author gt zynteglo tdt june
bluebird bio announc receiv eu condit market author lentiviral-bas ex vivo gt zynteglo
patient year older tdt genotyp hematopoiet stem cell
transplant would appropri human leukocyt antigen hla -match relat donor avail
author bluebird bio came zynteglo grant prime design ema zynteglo
also grant orphan drug breakthrough therapi design us fda
announc apceth biopharma privat oper commerci manufactur zynteglo eu
zynteglo author us repres valid use treat blood disord compani
develop genet medicin target tdt includ aruv scienc privat also use ex vivo lentiviral-
base approach well crispr buy unrat use crispr-
base zinc finger nucleas zfn -base gene edit approach respect
carisma privat announc appoint dr robert petit chief scientif offic june
aldevron privat announc construct gt manufactur campu north dakota june
ortx unrat announc price public offer mm common stock june
nk unrat announc launch phase trial t-hank cell therapi lymphoma june
nk unrat announc phase result ank/hank cell therapi advanced-stag solid tumor june
buy announc appoint rob ciappenelli chief commerci offic june
unrat announc mskcc present phase result car-t tx mesothelioma june
atara biotherapeut announc present collabor memori sloan ketter
cancer center mskcc result phase trial regionally-deliv autolog
car-t therapeut target mesothelin /- pembrolizumab advanc mesothelioma solid tumor
present built upon data previous present american associ cancer research annual
meet march addit higher dose cohort total
updat result continu encourag among mesothelioma patient also receiv
lymphodeplet therapi least dose pembrolizumab least month follow-up dose
overal surviv best overal respons rate orr includ complet
respons partial comparison orr similar patient would
note april research substanti progress car-t blood cancer see program
earli promis evid car-t activ solid tumor addit believ region deliveri rout could
contribut fairli clean tox profil seen car-t program
unrat announc fda clearanc ind bcma allogen car-t tx june
prevail tx privat announc fda clearanc ind gt parkinson june
casebia tx privat announc appoint stephen kennedi svp head technic oper june
feldan tx privat announc unrat tak unrat join quantum leap project june
feldan announc unrat takeda unrat join quantum leap project led
feldan cqdm total mm use optim feldan shuttl feldan proprietari protein
deliveri platform referenc feldan novemb present feldan shuttl also use
page
deliv crispr nucleas exist investor project includ sanofi unrat glaxosmithklin unrat
 unrat
cqdm consortium found support growth develop canadian biotech compani
fund come combin corpor partnership canadian govern regard addit
takeda quantum leap project canadian minist economi innov pierr fitzgibbon
state support project attest enorm potenti technolog develop qubec firm
buy announc complet roll submiss nda givosiran ahp june
unrat announc issuanc us patent rct program includ june
servier privat announc manufactur agreement yposkesi privat lentivir vector june
tng fp unrat announc peer-review public june
genethon privat publish preclin data crispr-bas gene edit june
nk unrat announc appoint cheryl cohen board director june
broad institut publish crispr-associ transposas cast catalyz gene edit june
compani mention report
page
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna krystal meira gtx expect initi trial
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
initi phase i/ii trial autosom recess congenit ichthyosi
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
initi phase dose escal studi danon diseas
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
initi phase i/ii trial adult phenylketonuria
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end june vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm genet therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm crispr pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap timevygr cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
cap refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrated/nr name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
